Previsão

Não temos dados de analistas para esta empresa.

Notícias Ir para o feed de notícias

Nexstim increases revenue in H1 2026 and reports record order backlog

Nexstim recorded a 16% revenue increase to EUR 5.2m in the first half of 2026, with a stable gross margin of around 80%. EBITDA was positive for the fourth consecutive half-year at EUR 0.3m, and recurring revenue rose 21% to EUR 2.5m (48% of net sales). Net profit remained negative at EUR -0.9m, weighed down by one-off financing expenses, while the order backlog reached a record level with more than ten additional system orders received after the end of June. Management maintains its 2026 guidance and points to stronger deliveries and further growth in recurring revenue. » Mais em de.investing.com
Nexstim reports strong revenue and earnings growth for H2 2025, shares fall sharply

Nexstim reports net revenue growth of 26% to €11m for the second half of 2025, and for the first time a positive operating profit and positive EBITDA. The company announces the market launch of the NBS‑6 system and aims for further revenue growth in 2026 as well as a mid-term annual growth rate of over 20% and an operating profit margin above 20%. Despite the positive figures, the stock fell 23.4% after publication, weighed down by market volatility and concerns about shifting the revenue model to software licensing. » Mais em de.investing.com

Dados financeiros da empresa

No último trimestre, Nexstim Oyj registou receitas de € 5,23 mi e um ganho líquido de -€ 861,9 mil

(EUR)	junho de 2026	YoY
Receitas	5,23 mi	-
Ganho bruto	4,18 mi	-
Ganho líquido	-861,9 mil	-
EBITDA	264,1 mil	-

Dados fundamentais

Métrica	Valor
Capitalização bolsista	€ 70,54 mi
Número de ações	7,23 mi
Máximo/mínimo de 52 semanas	€ 16,45 - € 7,89
Dividendos	Não
Beta	0,44
PER (PE Ratio)	975,00
PEG (PEG Ratio)	-19,00
P/VC (PB Ratio)	8,29
P/V (PS Ratio)	6,03

Perfil da empresa

Nexstim Plc, ein Medizintechnikunternehmen, entwickelt und vermarktet nicht-invasive Hirnstimulationstechnologien in Finnland, im übrigen Europa, in Nordamerika und international. Die firmeneigene SmartFocus-Technologie mit 3D-Navigation ist die navigierte transkranielle Magnetstimulation (TMS), die für therapeutische und diagnostische Anwendungen eingesetzt wird. Das Unternehmen bietet das NBT-System, ein navigiertes Hirntherapiesystem zur Behandlung von schweren Depressionen und chronischen neuropathischen Schmerzen, und das NBS-System, ein navigiertes Hirnstimulationssystem für die präoperative Kartierung der Sprach- und Motorkortexe des Gehirns. Das Unternehmen vertreibt seine NBS-Systeme hauptsächlich an Universitäten und Lehrkrankenhäuser. Nexstim Plc wurde im Jahr 2000 gegründet und hat seinen Hauptsitz in Helsinki, Finnland.